APAC Genetic Testing Market

Asia Pacific Genetic Testing Market Size (2022 to 2027)

The size of the Genetic Testing Market in the Asia Pacific was worth USD 10.60 billion in 2022 and is forecasted to reach USD 15.33 billion by 2027 growing at a CAGR of 7.65% during the forecast period.

As the need to provide superior healthcare due to advancements in healthcare is increasing, genetic testing has become a highly attractive segment in the molecular diagnostics market. The slightest modifications to the inherited disease condition, like chromosomes, genes, or proteins, can be identified through genetic testing. Genetic testing, which analyzes genes, chromosomes, or proteins, helps predict the risk of diseases, their diagnosis, the likely course of the disease, and identifying carriers (individuals not having the disease but having a copy of the disease gene) of the disease. Genetic testing has also helped easily diagnose diseases like sickle cell anemia, hemophilia, and cystic fibrosis, helping patients live normal life.

A few significant factors promoting the APAC genetic testing market are the growing awareness among individuals regarding the potential benefits of genetic testing. In addition, advancements and huge investments in the genetic testing space, a growing aging population, a rise in the number of chronic diseases, and increasing cancer cases are the other factors aiding the growth of the genetic testing market.

Cancer genetic testing is estimated to witness high growth and is most likely to accelerate the growth rate of the genetic testing market in this region during the forecast period. The market for screening newborns, diagnosing rare and fatal disorders, and estimating the probability of diseases is likely to expand. Particularly, genetic tests to screen newborns are expected to expand immensely. The growing frequency of genetic diseases unravels new opportunities for genetic testing and its related applications. It is anticipated that the transformation of genetic testing from a service-driven market to a product-driven market will push diagnostic companies to expand their operations.

However, a few factors affect the growth of the genetic testing market, like the authenticity of genetic reports being questioned due to a lack of credible standard procedure. And also, many individuals are concerned about the high cost associated with testing.

This research report on the APAC Genetic Testing Market has been segmented and sub-segmented into the following categories:

By Application: 

• Cancer Testing
• Pharmacogenomics Testing
• Prenatal Testing
• Predisposition Testing

By Test: 

• Carrier Testing
• Diagnostic Testing
• Prenatal Testing
• Neonatal Testing

By Country: 

• India
• China
• Japan
• South Korea
• Australia
• New Zealand
• Thailand
• Malaysia
• Vietnam
• Philippines
• Indonesia
• Singapore
• Rest of APAC

Regional Analysis:

Geographically, the Indian genetic testing market is the fastest-growing country in the Asia Pacific market due to various diseases and development in the healthcare sector. 

The Chinese genetic testing market has the largest growth in the APAC market due to rising genetic disorders in China. Recently, the China government has taken the initiative in genetic science development. 

The Japanese genetic testing market is expected to grow healthy in the coming years. Life sciences companies focus on screening tests for cancer and the introduction of DNA testing in Japan and South Korea, driving the demand for the genetic testing market.

The contract research organization (CRO) PPD and Neo genomic specialize in cancer genetic testing, and it started new laboratory services in Singapore for clinical trials. Also, development in healthcare sectors and implementation of innovative techniques in the Singapore genetic testing market foresee growth in Asia-Pacific.

KEY MARKET PLAYERS:

A few of the prominent companies dominating the APAC Genetic Testing Market profiled in this report are Abbott Laboratories, Roche Molecular Diagnostics Inc., Abbott Molecular Inc., AutoGenomics Inc., Celera Group, ELITech Group, BioRad Laboratories, PerkinElmer Inc., Quest Diagnostics Inc., Transgenomic Inc., and Applied Biosystems Inc.